Deep learning reads the genome to flag ALS risk in over 47,000 people

Neurologists have long faced a frustrating paradox in amyotrophic lateral sclerosis, the relentless motor neuron disease better known as ALS or motor neurone disease. Genetics clearly matters: twin studies, family clustering and genome-wide association analyses all point to an inherited component in the great majority of patients, including those with no family history at all. Yet the genetic tests that clinics actually use explain only a small slice of the disease, and they work almost exclusively for the 15 to 20 percent of patients who carry a known pathogenic mutation in genes such as C9orf72, SOD1, FUS or TARDBP. For the other 80 to 85 percent, the so-called sporadic cases that make up more than 90 percent of all ALS, a negative genetic test tells you almost nothing. A new study published in Genome Medicine argues that a different kind of reading of the genome, one performed by a deep learning architecture originally inspired by how the visual brain parses objects, could begin to close that gap.

The research, led by Jiajing Hu and Alfredo Iacoangeli at King’s College London together with Ammar Al-Chalabi, Alexander Schönhuth and a large international network of ALS clinicians, builds on an earlier observation that Capsule Networks, or CapsNets, can learn to distinguish people with ALS from unaffected controls using nothing more than single nucleotide polymorphism genotyping data. CapsNets are a relative newcomer to the deep learning menagerie. Where conventional convolutional neural networks compress spatial information into a single scalar output at each layer, capsules preserve the pose and identity of features as vectors, allowing the network to reason explicitly about part-whole relationships. In genomics, that means the model can, in principle, capture how variants within a gene or pathway combine, rather than treating each single nucleotide polymorphism as an independent bit of evidence. The catch, until now, has been that published CapsNet experiments were confined to specific datasets and genotyping platforms, leaving open whether the approach would generalise beyond the population and the chip it was trained on.

The new work tackles that generalisation problem head-on with a dataset of unusual scale for this disease. The team assembled genetic data from more than 47,000 individuals across 13 countries, drawing on the Project MinE consortium and collaborating ALS centres in Europe, North America, the Middle East and Australia. Crucially, the samples were genotyped on nine different platforms, each of which interrogates a slightly different set of variants and produces its own batch effects, missingness patterns and allele-calling quirks. Any model that silently learns the fingerprint of a particular genotyping chip will fail the moment it meets a patient typed on another one, a failure mode that has plagued machine learning applications in medicine. The researchers therefore engineered their pipeline to be robust to these technical discrepancies, using quality control procedures, principal component analysis to characterise and adjust for ancestry, and a gene-based principal component strategy that compresses variant-level information into gene-level features before the network ever sees it.

That gene-based dimensionality reduction is one of the study’s key technical moves. Rather than feeding hundreds of thousands of raw SNP genotypes into the CapsNet, the authors aggregate variants by gene, computing principal components that summarise each individual’s genetic variation within each gene region. This does two things at once. It shrinks the input space to a size the network can learn from without overfitting, and it anchors the features in biological units, genes, that are shared across genotyping platforms even when the exact SNP content differs. The capsules then operate on these gene-level representations, and the routing-by-agreement mechanism of the CapsNet allows lower-level gene features to vote on the higher-level decision of whether the genome belongs to someone with ALS. The result is a model that is flexible enough to accept an individual external sample, whatever platform produced it, and still produce a calibrated risk estimate.

The performance results are striking for a disease whose common genetic architecture has proved so elusive. In external validation across diverse ALS populations from multiple countries, the model achieved high precision and sensitivity in separating individuals with ALS from unaffected controls, holding up despite the technical and ancestral heterogeneity of the data. The authors are careful to frame this as risk stratification and diagnostic support rather than a stand-alone diagnosis; the model does not replace clinical examination, electromyography or targeted mutation testing. But the ability to extract a disease signal from genome-wide genotyping data in sporadic ALS, where classical genetics has explained so little, suggests that the collective weight of thousands of common variants, and the nonlinear interactions among them, carries real information that linear polygenic risk scores have struggled to capture.

Perhaps the most provocative result comes from a simulation. The team modelled what would happen if the tool were deployed as a population screening test for ALS, and found that its predictive performance under that scenario was comparable to published estimates for screening based on the major known ALS-causing mutations such as FUS and C9orf72. That comparison matters because mutation-based screening only works for carriers of those specific variants, whereas the deep learning model applies to everyone. In effect, the study suggests that a genome-wide pattern learned by a neural network can match the yield of looking for the single most consequential known mutations, at least in the simulated screening context. If that holds up prospectively, it would mean genetic risk assessment could be extended to all individuals regardless of family history or mutation status, a genuine democratisation of ALS genetics.

The clinical logic is compelling because ALS is a disease where time is function. The average diagnostic delay from first symptoms to confirmed diagnosis remains long, often around a year, and there is growing evidence that the earlier treatment begins, the better the outcome. Riluzole, the oldest approved therapy, and the newer antisense and antibody-based approaches now entering the clinic all work best early. A validated genomic risk score could flag individuals at elevated risk for closer monitoring, help neurologists interpret ambiguous early presentations, and, once a diagnosis is made, contribute to prognostic stratification. The authors are explicit that their tool supports, rather than replaces, existing genetic testing: for the minority of patients with known pathogenic variants, targeted testing remains essential, particularly since those variants now determine eligibility for precision therapies such as antisense oligonucleotides.

The study also carries a sober set of caveats that the authors do not shy away from. The model was trained and validated on case-control data, which is the right starting point but not the same as predicting who will develop disease in a healthy population. ALS is rare, so even a highly precise classifier will generate false positives at population scale, and the ethical weight of telling a healthy person they carry elevated risk for a uniformly fatal disease is enormous. Ancestry is another live concern: despite the international scope of the dataset, most participants are of European descent, and the authors stress that further prospective clinical validation in diverse populations is required before any diagnostic use. The team’s own conclusion is measured: the method could support genetic risk stratification now, and diagnostic support in the future, but only after that prospective validation is done.

What makes the work resonate beyond ALS is its demonstration that deep learning can extract clinically meaningful signal from the genomic dark matter of a complex neurodegenerative disease. Capsule Networks were designed for computer vision, and their migration into genomics is part of a broader convergence in which architectures built for one domain prove unexpectedly adept at another. The gene-based principal component trick, the platform-agnostic preprocessing and the multi-country external validation form a template that other common-disease geneticists can copy. For the ALS community, which has watched genetic discoveries accumulate without translating into risk prediction for most patients, the study offers something rarer than a new gene: a working bridge between the genome-wide association era and the clinic. The 47,000 genomes behind the model were donated by patients and families across 13 countries, and the authors dedicate the tool’s promise to exactly that population, the sporadic cases who have, until now, been told their genetics held no answers.

Subject of Research: Deep learning genomic risk prediction for sporadic amyotrophic lateral sclerosis

Article Title: Towards a deep-learning genomic tool for risk stratification and diagnostic support in sporadic ALS

Article References: Hu, J., Pain, O., Al Khleifat, A., Shatunov, A., Andersen, P. M., Başak, N. A., Cooper-Knock, J., Corcia, P., Couratier, P., de Carvalho, M., Drory, V., Gotkine, M., Landers, J. E., Glass, J. D., McLaughlin, R., Pardina, J. S. M., Morrison, K. E., Pinto, S., Povedano, M., … Iacoangeli, A. (2026). Towards a deep-learning genomic tool for risk stratification and diagnostic support in sporadic ALS. Genome Medicine. https://doi.org/10.1186/s13073-026-01744-5

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01744-5

Keywords: ALS, deep learning, Capsule Networks, genomics, risk stratification, sporadic ALS, Project MinE, polygenic risk, genome-wide association study, diagnostic support, C9orf72, Genome Medicine